RT Journal Article
SR Electronic
T1 Correlation of ELISA based with random access serologic immunoassays for identifying adaptive immune response to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.06.20145938
DO 10.1101/2020.07.06.20145938
A1 Nguyen, Nguyen N.
A1 Mutnal, Manohar B.
A1 Gomez, Richard R.
A1 Pham, Huy N.
A1 Nguyen, Lam T.
A1 Koss, William
A1 Rao, Arundhati
A1 Arroliga, Alejandro C.
A1 Wang, Liping
A1 Wang, Dapeng
A1 Hua, Yinan
A1 Powell, Priscilla R.
A1 Chen, Li
A1 McCormack, Colin C.
A1 Linz, Walter J.
A1 Mohammad, Amin A.
YR 2020
UL http://medrxiv.org/content/early/2020/07/08/2020.07.06.20145938.abstract
AB Public health emergency of SARS-CoV-2 has facilitated diagnostic testing as a related medical countermeasure against COVID-19 outbreak. Numerous serologic antibody tests have become available through an expedited federal emergency use only process. This paper highlights the analytical characteristic of an ELISA based assay by AnshLabs and three random access immunoassay (RAIA) by DiaSorin, Roche, and Abbott that have been approved for emergency use authorization (EUA), at a tertiary academic center in a low disease-prevalence area. The AnshLabs gave higher estimates of sero-prevalence, over the three RAIA methods. For positive results, AnshLabs had 93.3% and 100% concordance with DiaSorin or Abbott and Roche respectively. For negative results, AnshLabs had 69.7% and 73.0% concordance with DiaSorin and Roche or Abbott respectively. All discrepant samples that were positive by AnshLabs and negative by RAIA tested positive by all-in-one step SARS-CoV-2 Total (COV2T) assay performed on the automated Siemens Advia Centaur XPT analyzer. None of these methods, however, are useful in early diagnosis of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBaylor Scott & White research fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Baylor Scott and White Health (BSWH) Institutional Review board. This evaluation project was undertaken as a quality improvement initiative at our institution and as such was not formally supervised by the Institutional Review Board, per their policies on quality improvement initiative.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be given upon request